Ascletis Pharma Inc. (HKEX: 1672), a China-based biopharmaceutical company, announced today that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096). This move marks a major milestone in the development of ritonavir tablets and establishes a strong partnership between Ascletis and Simcere.
Ritonavir tablets are the only authorized oral antiviral protease inhibitor booster in China. Ascletis has completed the necessary bioequivalence study, making it the go-to tablet for those in need of a pharmacokinetic booster. With this tablet, you’ll be able to effectively treat your condition and get back to your life.
Ascletis is a revolutionary biotech company listed on the Hong Kong Stock Exchange (1672.HK). With a team of experts and a proven track record, Ascletis is committed to tackling global unmet medical needs in three therapeutic areas: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. The company has made impressive progress in its pipeline, having already marketed three products – ritonavir tablets, GANOVO® and ASCLEVIR® – and currently having 22 drug candidates in development. The most advanced of these include ASC22 (CHB functional cure), ASC10 and ASC11 (oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). With such a powerful portfolio, Ascletis is well-positioned to become a global leader in the healthcare industry.